Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 885 Characterization of the tu...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

Bibliographic Details
Main Authors: Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
    by: Dong Zhou, et al.
    Published: (2021-05-01)
  • Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
    by: Jiaguo Li, et al.
    Published: (2020-01-01)
  • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
    by: Stergios Boussios, et al.
    Published: (2020-03-01)
  • Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    by: Shicheng Yang, et al.
    Published: (2023-05-01)
  • Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.
    by: Florian Schwarz, et al.
    Published: (2022-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs